Lacticaseibacillus paracasei AO356 ameliorates obesity by regulating adipogenesis and thermogenesis in C57BL/6J male mice

Obesity is a metabolic disease caused by the excessive fat accumulation and is a global health problem that affects more than one-third of the population. Probiotics are considered an effective alternate treatment for preventing obesity as FDA-approved anti-obesity drugs are associated with side effects, such as depression, diarrhea, and dyspepsia. Oral administration of Lacticaseibacillus paracasei AO356 (AO356) isolated from healthy female Koreans to high-fat diet-fed C57BL/6J male mice effectively ameliorated body weight gain, abnormal body composition, and obesity-induced hyperleptinemia and inflammation. This effect may be associated with the downregulation of adipogenesis transcription factor-and lipid metabolism related genes, such as Srebp1c, Ppar gamma, Fas, C/ebp alpha, and Fabp4 and upregulation of thermogenesis-related genes, such as Ucp1, Cpt1, Pgc1 alpha, Cidea, and Prdm16 in epididymal and subcutaneous fat pads. In conclusion, our results show that AO356 prevents highfat diet-induced obesity by regulating adipogenesis and thermogenesis.

Automated summary

Obesity is a global health problem affecting over one-third of the population and is caused by excessive fat accumulation. Probiotics, such as Lacticaseibacillus paracasei AO356, have been found to be an effective alternative treatment for preventing obesity without the side effects associated with FDA-approved anti-obesity drugs. Oral administration of AO356 to high-fat diet-fed mice resulted in a significant decrease in body weight gain, abnormal body composition, and obesity-related health issues through regulating adipogenesis and thermogenesis.